A recent publication in the Lancet’s eBioMedicine journal, identified three novel compounds for the treatment of ADPKD. The researchers used a novel approach that combines bio and chemo-informatics where the Euretos AI Platform was used in the preselection of potential drug repurposing candidates.As the researchers stated: “Our filtering steps aim to minimize the number of ‘wet-lab’ experiments by focusing on only the most relevant and most confident information from literature.”
As the publication shows, in-silico and computational approaches can significantly improve the effectiveness of the drug development process. In the area of drug repurposing, Euretos has multiple references showing the effectiveness of using AI driven computational disease models to drive Indication Expansion.
To identify new candidate drugs for the ADPKD drug development pipeline, the team evaluated six compounds in a 3D Cyst assay. The six candidate drugs, Zileuton, Indometacin, Meclofenamic Acid, Gamolenic Acid, icosapent and Birinapant were selected based on evidence for the potential therapeutic potential for ADPKD present in the Euretos AI Platform and the subsequent review of available scientific literature.